Quest, Vermillion Begin U.S. Marketing Push For Ovarian Cancer Test
This article was originally published in The Gray Sheet
Executive Summary
Quest Diagnostics will leverage its know-how of the women's health care segment and relationships with OB/GYNs to market Vermillion's OVA1, the first FDA-cleared blood test to help assess potentially malignant ovarian tumors prior to surgery
You may also be interested in...
Vermillion Takes Control: Dx Firm Launches Its Own Lab To Market Ovarian Cancer Test
Not happy with market penetration since its FDA-cleared OVA1 ovarian cancer molecular assay launched exclusively via Quest Diagnostics in 2009, Vermillion has launched ASPiRA Labs to more directly connect with OB-GYN customers.
Washington Roundup, February 2013
The latest medical device regulatory and reimbursement news from Elsevier Business Intelligence’s “The Gray Sheet.”
Blues’ TEC Delivers Mostly Negative Assessments For Three Technologies
The Blue Cross Blue Shield Technology Evaluation Center considered balloon ostial dilation for the treatment for chronic rhinosinusitis; multianalyte testing for evaluation of adnexal masses; and nucleic acid sequencing-based testing of maternal plasma for fetal aneuploidy.